Literature DB >> 20725862

Quiescent T cells and HIV: an unresolved relationship.

Dimitrios N Vatakis1, Christopher C Nixon, Jerome A Zack.   

Abstract

The ability of HIV to infect quiescent CD4+ T cells has been a topic of intense debate. While early studies suggested that the virus could not infect this particular T cell subset, subsequent studies using more sensitive protocols demonstrated that these cells could inefficiently support HIV infection. Additional studies showed that the kinetics of infection in quiescent cells was delayed and multiple stages of the viral life cycle were marred by inefficiencies. Despite that, proviral DNA has been found in these cells presenting them as a potential viral reservoir. Therefore, a better understanding of the relationship between HIV and quiescent T cells may lead to further advances in the field of HIV.

Entities:  

Mesh:

Year:  2010        PMID: 20725862      PMCID: PMC3824961          DOI: 10.1007/s12026-010-8171-0

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  85 in total

1.  Lung Krüpple-like factor: a quintessential player in T cell quiescence.

Authors:  J P Di Santo
Journal:  Nat Immunol       Date:  2001-08       Impact factor: 25.606

2.  Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells.

Authors:  Dimitrios N Vatakis; Gregory Bristol; Thomas A Wilkinson; Samson A Chow; Jerome A Zack
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

3.  TLR2 signaling renders quiescent naive and memory CD4+ T cells more susceptible to productive infection with X4 and R5 HIV-type 1.

Authors:  Sandra Thibault; Mélanie R Tardif; Corinne Barat; Michel J Tremblay
Journal:  J Immunol       Date:  2007-10-01       Impact factor: 5.422

4.  HIV-1 integrates into resting CD4+ T cells even at low inoculums as demonstrated with an improved assay for HIV-1 integration.

Authors:  Luis M Agosto; Jianqing J Yu; Jihong Dai; Rachel Kaletsky; Daphne Monie; Una O'Doherty
Journal:  Virology       Date:  2007-07-13       Impact factor: 3.616

Review 5.  A brief introduction to FOXOlogy.

Authors:  B M Th Burgering
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

Review 6.  Foxo in the immune system.

Authors:  S L Peng
Journal:  Oncogene       Date:  2008-04-07       Impact factor: 9.867

Review 7.  Tob genes in development and homeostasis.

Authors:  Shunji Jia; Anming Meng
Journal:  Dev Dyn       Date:  2007-04       Impact factor: 3.780

8.  Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells.

Authors:  Gabriela Plesa; Jihong Dai; Cliff Baytop; James L Riley; Carl H June; Una O'Doherty
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

9.  CCR7 ligands CCL19 and CCL21 increase permissiveness of resting memory CD4+ T cells to HIV-1 infection: a novel model of HIV-1 latency.

Authors:  Suha Saleh; Ajantha Solomon; Fiona Wightman; Miranda Xhilaga; Paul U Cameron; Sharon R Lewin
Journal:  Blood       Date:  2007-09-19       Impact factor: 22.113

10.  KLF4 is a FOXO target gene that suppresses B cell proliferation.

Authors:  Isharat Yusuf; Michael G Kharas; Jing Chen; Raechel Q Peralta; Autumn Maruniak; Pratibha Sareen; Vincent W Yang; Klaus H Kaestner; David A Fruman
Journal:  Int Immunol       Date:  2008-03-28       Impact factor: 4.823

View more
  20 in total

1.  Glut1-mediated glucose transport regulates HIV infection.

Authors:  Séverine Loisel-Meyer; Louise Swainson; Marco Craveiro; Leal Oburoglu; Cédric Mongellaz; Caroline Costa; Marion Martinez; François-Loic Cosset; Jean-Luc Battini; Leonard A Herzenberg; Leonore A Herzenberg; Kondala R Atkuri; Marc Sitbon; Sandrina Kinet; Els Verhoeyen; Naomi Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 2.  HIV reservoirs and latency models.

Authors:  Matthew J Pace; Luis Agosto; Erin H Graf; Una O'Doherty
Journal:  Virology       Date:  2011-02-01       Impact factor: 3.616

3.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

4.  Restricting HIV the SAMHD1 way: through nucleotide starvation.

Authors:  Diana Ayinde; Nicoletta Casartelli; Olivier Schwartz
Journal:  Nat Rev Microbiol       Date:  2012-08-28       Impact factor: 60.633

Review 5.  Attacking the HIV reservoir from the immune and viral perspective.

Authors:  Marta Massanella; Javier Martinez-Picado; Julià Blanco
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

6.  The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!

Authors:  Vladimir Temchura; Matthias Tenbusch
Journal:  Virol Sin       Date:  2014-02       Impact factor: 4.327

7.  Potent Inhibition of HIV-1 Replication in Resting CD4 T Cells by Resveratrol and Pterostilbene.

Authors:  Chi N Chan; Benjamin Trinité; David N Levy
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

8.  The therapeutic potential of adenosine triphosphate as an immune modulator in the treatment of HIV/AIDS: a combination approach with HAART.

Authors:  Marc C E Wagner
Journal:  Curr HIV Res       Date:  2011-06       Impact factor: 1.581

9.  Directly infected resting CD4+T cells can produce HIV Gag without spreading infection in a model of HIV latency.

Authors:  Matthew J Pace; Erin H Graf; Luis M Agosto; Angela M Mexas; Frances Male; Troy Brady; Frederic D Bushman; Una O'Doherty
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.